<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01974375</url>
  </required_header>
  <id_info>
    <org_study_id>MYC-LT-01</org_study_id>
    <nct_id>NCT01974375</nct_id>
  </id_info>
  <brief_title>Micafungin Versus Fluconazole for Prevention of Invasive Fungal Disease in Living Donor Liver Transplant Recipients</brief_title>
  <acronym>KOPIN</acronym>
  <official_title>Randomized, Open Label, Non-inferiority Study of Micafungin Versus Fluconazole for the Korean Prevention of Invasive Fungal Disease in Living Donor Liver Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate non-inferiority of micafungin at a dose of 100
      mg/day versus fluconzeole for the prevention of Invasive Fungal Disease, defined according to
      the revised EORTC/MSG criteria, undergoing living-donor liver transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is Randomized, Open label, Non-inferiority Study of Micafungin versus Fluconazole for
      the Korean Prevention of Invasive Fungal Disease in Living Donor Liver Transplant Recipients

      After transplant subjects will be randomized to one of the following treatment arms:

        -  Micafungin 100 mg/day intravenous (2.0 mg/kg/day in subjects weighing &lt;40 kg)

        -  Fluconazole 100~200mg/day, IV care until oral medication becomes possible

      Stratification according to centers. Antifungal prophylaxis will be administered once daily
      for a period of 21 days, or until hospital discharge, whichever occurs first.

      This is an open label study; Study center personnel will not be blinded to treatment.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevention of invasive fungal disease</measure>
    <time_frame>6 months</time_frame>
    <description>To demonstrate non-inferiority of micafungin at a dose of 100 mg/day versus fluconzeole for the prevention of Invasive Fungal Disease, defined according to the revised EORTC/MSG criteria, undergoing living-donor liver transplantation.
'Clinical success' at the End of Prophylaxis as assessed by the investigator.
Absence of a 'proven' or 'probable' IFD AND No initiation of antifungal treatment (additional antifungal medication or increase in the dose of the study drug due to lack of efficacy)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>no events of proven/probable IFD</measure>
    <time_frame>6 months</time_frame>
    <description>no events of proven/probable IFD at end of prophylaxis visit and end of study visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ime to proven/probable IFD</measure>
    <time_frame>6 months</time_frame>
    <description>Time to proven/probable IFD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fungal-free survival</measure>
    <time_frame>6 months</time_frame>
    <description>fungal-free survival et end of study/and long-term follow-up visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of superficial mycosis infection and colonization</measure>
    <time_frame>6 months</time_frame>
    <description>incidence of superficial mycosis infection and colonization at the end of prophylaxis compare to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>saftey by variables</measure>
    <time_frame>6 months</time_frame>
    <description>saftey by variables of viatl sign/physical examination/laboratory test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cases of adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>cases of adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">172</enrollment>
  <condition>Liver Transplant Recipient</condition>
  <arm_group>
    <arm_group_label>micafungin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>micafungin sodium IV (MycamineÂ®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluconazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluconazole IV (use same brand in each hospital)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>micafungin</intervention_name>
    <description>Micafungin 100 mg/day intravenous (2.0 mg/kg/day in subjects weighing &lt;40 kg)</description>
    <arm_group_label>micafungin</arm_group_label>
    <other_name>Mycamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole</intervention_name>
    <description>Fluconazole 100~200mg/day, IV care until oral medication becomes possible</description>
    <arm_group_label>Fluconazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 20 years.

          -  Undergoing Living Donor Liver Transplantation(LDLT)

        Exclusion Criteria:

          -  Any systemic antifungal therapy (excluding fluconazole or SDD for a maximum of 7 days)
             within 14 days prior to randomization.

          -  Evidence of documented ('proven' or 'probable') or suspected ('possible') IFD
             (according to the EORTC/MSG criteria).

          -  Allergy, hypersensitivity, or any serious reaction to an echinocandin antifungal, or
             any of the study drugs or their excipients.

          -  Reimplantation or orthotopic transplantation patient.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SUNG-GYU LEE, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giwon Song, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Namjoon Lee, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jaewon Joh, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dong-Lak Choi, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Daegu Catholic University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Myung Soo Kim, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giwon Song, Professor</last_name>
    <phone>+82-10-8794-8701</phone>
    <email>drsong71@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giwon Song, Professor</last_name>
      <phone>+82-10-8794-8701</phone>
      <email>drsong71@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2013</study_first_submitted>
  <study_first_submitted_qc>October 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2013</study_first_posted>
  <last_update_submitted>October 27, 2013</last_update_submitted>
  <last_update_submitted_qc>October 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Giwon Song</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Living donor</keyword>
  <keyword>Liver transplant</keyword>
  <keyword>antifungal prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Invasive Fungal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluconazole</mesh_term>
    <mesh_term>Micafungin</mesh_term>
    <mesh_term>Echinocandins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

